Journal ArticleDOI
Treatment of the primary tumor in metastatic prostate cancer.
TLDR
The existing data evaluatingPrimary tumor therapy for patients with metastatic prostate cancer is reviewed and ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with prostate cancer are described.Abstract:
The cornerstone of treatment for metastatic prostate cancer patients has been conventional androgen deprivation therapy, with additional systemic therapy initiated only after castration resistance, and local therapy reserved for palliation. Compelling results from modern trials challenge this paradigm, arguing for initiating escalated hormone therapy and/or chemotherapy during the castration-sensitive disease state for many patients. Furthermore, modern radiotherapy techniques allow for local control of disease with low risk of toxicity. Finally, new PET probes with enhanced sensitivity and accuracy are likely to become a part of routine staging and will lead to an increased incidence of patients with metastatic disease at presentation, with a shift toward identification of patients with limited metastatic disease. As such, the landscape is primed for investigations aimed to explore the role of primary tumor therapy for patients with metastatic prostate cancer. We review the existing data evaluating primary tumor therapy for patients with metastatic prostate cancer and describe ongoing clinical trials testing the hypothesis that primary tumor therapy may benefit patients with metastatic prostate cancer.read more
Citations
More filters
Journal ArticleDOI
Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting
Shafak S Aluwini,Niven Mehra,Martijn P. Lolkema,Daniela E. Oprea-Lager,Derya Yakar,Herman Stoevelaar,Henk G. van der Poel,Martijn B. Busstra,Igle-Jan de Jong,Theo M. de Reijke,Kim de Vries,Stijn W.T.P.J. Heijmink,Guido Jenster,Sjoerd O. Klaver,Jeroen Kneppers,Jules Lavalaye,Gisele H. J. M. Leyten,Luc M.F. Moonen,James Nagaraj,Walter Noordzij,Susanne Osanto,Irma M. Oving,Eva E. Schaake,Tom W. J. Scheenen,Ivo G. Schoots,Michiel Sedelaar,Diederik M. Somford,Franchette W P J van den Berkmortel,Tom van der Hulle,Jochem R.N. van der Voort van Zyp,Pim J. van Leeuwen,Jeroen van Moorselaar,Inge M. van Oort,Wouter V. Vogel,Hans M. Westgeest +34 more
TL;DR: A multidisciplinary panel reached a consensus that Oligometastatic prostate cancer patients having few metastases may benefit from a new therapeutic approach, and is a specific disease state requiring a tailored treatment approach.
Journal ArticleDOI
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
Amar U. Kishan,Fang-I Chu,Christopher R. King,W. Seiferheld,Daniel E. Spratt,Phuoc T. Tran,Xiaoyan Wang,Stephanie E. Pugh,Kiri A. Sandler,Michel Bolla,Philippe Maingon,Theo M. de Reijke,Nicholas G. Nickols,Nicholas G. Nickols,Matthew Rettig,Alexandra Drakaki,Sandy T. Liu,Robert E. Reiter,Albert J. Chang,Felix Y. Feng,Dipti Sajed,Paul L. Nguyen,Patrick A. Kupelian,Michael L. Steinberg,Paul C. Boutros,David Elashoff,Laurence Collette,Howard M. Sandler +27 more
TL;DR: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events that warrant consideration for intervention.
Journal ArticleDOI
Loss of testosterone impairs anti-tumor neutrophil function.
Janet L. Markman,Rebecca A. Porritt,Daiko Wakita,Malcolm Lane,Daisy Martinon,Magali Noval Rivas,Michael Luu,Edwin M. Posadas,Timothy R. Crother,Moshe Arditi +9 more
TL;DR: It is shown that in castrated male mice, neutrophil maturation and function are impaired, leading to elevated metastatic burden in two models of melanoma, and the aberrant neutrophIL phenotype was also observed in prostate cancer patients receiving androgen deprivation therapy, highlighting the evolutionary conservation and clinical relevance of the phenotype.
Journal ArticleDOI
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Neil R. Parikh,Claudia Huiza,Jill S. Patel,Sonny Tsai,Nathisha Kalpage,May S Thein,Sage Pitcher,Steve P. Lee,Warren S. Inouye,Mark L. Jordan,Homayoon Sanati,Lida Jafari,Carol J. Bennett,Greg Gin,Amar U. Kishan,Robert E. Reiter,Michael T. Lewis,Ahmad Sadeghi,William J. Aronson,William J. Aronson,Isla P. Garraway,Isla P. Garraway,Matthew Rettig,Nicholas G. Nickols +23 more
TL;DR: This Phase II single-arm clinical trial combines local, metastasis-directed, and systemic therapies to durably render patients free of detectable disease off active therapy to represent the critical first step towards curative intent therapy for a patient population where palliation has been the norm.
Journal ArticleDOI
Navigating systemic therapy for metastatic castration-naïve prostate cancer
Edmond M. Kwan,Isaac Thangasamy,Jiasian Teh,Omar Alghazo,Niranjan J. Sathianathen,Nathan Lawrentschuk,Nathan Lawrentschuk,Arun Azad +7 more
TL;DR: Current data support consideration of upfront docetaxel in all patients, regardless of metastatic burden, and decisions regarding systemic treatment for men with mCNPC should be based on comprehensive consideration of disease, patient and logistical factors.
References
More filters
Journal ArticleDOI
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
TL;DR: Gutman et al. as mentioned in this paper showed that the acid phosphatase of serum is reduced in metastatic carcinoma of the prostate by decreasing the activity of androgens through castration or estrogenic injections and that this enzyme is increased by injecting androgens.
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher Sweeney,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Mario A. Eisenberger,Yu-Ning Wong,Noah M. Hahn,Manish Kohli,Matthew M. Cooney,Robert Dreicer,Nicholas J. Vogelzang,Joel Picus,Daniel H. Shevrin,Maha Hussain,Jorge A. Garcia,Robert S. DiPaola +16 more
TL;DR: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
Journal ArticleDOI
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
TL;DR: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables.
Journal ArticleDOI
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan,Sydney E. Salmon,Brent A. Blumenstein,Scott I. Bearman,Vivek Roy,Patrick C. McGrath,John R. Caton,Nikhil C. Munshi,E. David Crawford +8 more
TL;DR: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.